Lundbeck closes RNA deal worth USD 109m with US biotech firm
Danish pharmaceutical firm Lundbeck enters a strategic collaboration with US biotech group Rgenta in order to find small molecules targeting RNA and develop new treatments for neurological diseases. To start with, the Danish company pays DKK 63m, and in time, it might end up paying DKK 628m in milestone payments.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN & DANIEL FRANK CHRISTENSEN
New treatments for rare brain diseases in a potentially very lucrative market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Takeda surpasses analyst forecasts in Q1
For subscribers
Lundbeck to trial migraine drug in young people
For subscribers
.jpg&w=384&q=75)
